Family Heart Foundation/X
Aug 26, 2025, 09:45
FDA Expands Repatha (Evolocumab) Approval: New Options for Adults With Uncontrolled LDL-C and HoFH
Family Heart Foundation posted on X:
”FDA expands approval of Repatha® (evolocumab) for adults at risk of CV events from uncontrolled LDL-C—even without established CVD. Now approved as monotherapy for HoFH. Important update for clinicians managing FH patients.”
Find more information here.
Stay updated with Hemostasis Today.
-
Nov 20, 2026, 00:33Overcoming Barriers to Diagnosis and Treatment for Women With Bleeding Disorders – EHC
-
Nov 20, 2026, 00:27Vera Stroikova: Key Takeaways on Electrophysiology and Stroke Prevention From the New Horizons 2026
-
Nov 20, 2026, 00:20Devi G. Nair Enrolls First US Patient in Smartphone Camera Atrial Fibrillation Detection Study
-
Nov 20, 2026, 00:14Saskia de Pee: Fortified Rice Cuts Anemia Risk by 57%
-
Nov 20, 2026, 00:02Andres Zuleta: Evaluating the RISE UP Trial Results on Mitapivat for Sickle Cell Disease
-
Nov 19, 2026, 23:57Greta Hametner: Preventing Maternal Cardiac Complications Through Preconception Iron and Thyroid Screening
-
Nov 19, 2026, 23:49Cyrus Shariat: Why Waiting for Lab Results Can Be Fatal in HIT
-
Nov 19, 2026, 22:24Erik Nelson: Low Iron Can Raise A1c without Changing Blood Sugar
-
Nov 19, 2026, 22:23Erwin Loh: Daily Iron Supplementation Reduces Iron-Deficiency Anaemia in Children and Adolescents